From Recent Issues

Hemophagocytic Lymphohistiocytosis: New Grading Classification and Targeted Therapies

Abstract: Hemophagocytic lymphohistiocytosis (HLH), both primary/familial HLH and secondary HLH, is associated with multiorgan dysfunction caused by excessive immune activation and cytokine release. The high morbidity […]

Is There an Optimal Sequential Order to Androgen Receptor Axis Therapeutics?

Abstract: The hormonal therapeutic landscape in prostate cancer has expanded greatly over the last few decades with the advent of abiraterone acetate and second-generation antiandrogens such […]

Multikinase Inhibitors in Refractory Metastatic Colorectal Cancer: An Optimal Sequence?

Abstract: Despite major advances in management strategies, metastatic colorectal cancer remains an important clinical challenge because most patients experience progression after standard first- and second-line treatments. […]

Supplements

Use of Ravulizumab in a Pregnant Patient With PNH: Case-Based Insights

About the Patient AK has been under the care of my practice for several years, and her case is notably complex (Table). This case demonstrates that, […]

Ravulizumab–Danicopan Combination Therapy in PNH Management

In the Clinic AB presented to our clinic in 2017, at the age of 70, for a second opinion regarding management of paroxysmal nocturnal hemoglobinuria (PNH) […]

Translating FRESCO Clinical Trial Evidence Into Practice: Fruquintinib as Post–Standard Third-Line Therapy Followed by Trifluridine/Tipiracil in a Patient With mCRC Without Targetable Mutations

In the Clinic JR is a 54-year-old male who was diagnosed with left-side transverse colon adenocarcinoma metastatic to the peritoneum and liver (Table 1). A next-generation […]